Vitro in Medical Technology

New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria

WASHINGTON, Oct. 27 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced new study results that demonstrate doripenem (DORIBAX(TM), doripenem for injection), a carbapenem antibiotic, was found to be more potent in vitro against certain strai...

Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor

WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two studies on SPI-256, a novel investigational HIV protease inhibitor (PI). One study based on an in vitro analysis demonstrates that the mode of interaction of SPI-256 with HIV protease provides...

MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe

Acceptance Will Reduce Animal Use in Cosmetics and Chemicals Testing ASHLAND, Mass., Oct. 8 /PRNewswire/ -- MatTek Corp. today announced that results of a recently completed US and European multi-laboratory "catch-up" validation study on MatTek's EpiDerm in vitro human skin tissue equivalent...

Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from completed studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against a variety of susceptible and resistant strains of gra...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

Prodrugs Generated from Targanta's Novel Drug Discovery Platform CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from two studies highlighting the in vitro activity and in vivo efficacy of its proprietary prodrugs in osteomyelitis models. Re...

Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria

Novel Antibiotic Candidate Rapidly Bactericidal Against Both Cultures and Spores of the Anaerobic Bacterium Using Multiple in Vitro Methods CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released data from two studies comparing the in vitro activity of its lead anti...

Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World

Georgia Reproductive Specialists is First to Evaluate New, Patient-Friendly Progesterone Supplement ATLANTA, Aug. 2 /PRNewswire/ -- Georgia Reproductive Specialists in Atlanta, GA was one of 25 sites nationwide that recently completed the largest in vitro fertilization (IV...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

Three Oritavancin Studies Presented at ECCMID/ICC MUNICH, Germany, April 03, 2007 /PRNewswire/ -- Targanta Therapeutics today announced results from two studies showing the improved potency of oritavancin to stop bacterial growth in vitro when tested with a common wetting agent (polysorbate 80) an...

ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants

Poster Presentation at EASL on April 13, 2007, 2007 SAN DIEGO, and SEOUL, South Korea, April 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd., presented data from an in vitro study showing that ANA380 (LB80380) retains potency against multiple mutant strains of ...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on i...

AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and...

terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUBEC CITY, Canada, April 16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company foc...

In Vitro and In Vivo Data Show Alfacell's Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells

Pre-Clinical Results Demonstrate Potential of ONCONASE for Treatment of Neuroblastoma BLOOMFIELD, N.J., June 27, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that new data show ONCONASE, the company's lead drug candidate, is active against naive and chemoresistant neuroblast...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...CV infection. PSI-7851 has demonstrated potent in vitro anti-HCV activity with EC(90) values of 31 +/- 12...e inhibitor, RG7128 (formerly known as R7128). In vitro studies of PSI-7851 have not shown evidence of an...SI-7851 has demonstrated pan genotype activity in vitro . About Pharmasset Pharmasset is a cli...

VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

...ay using an integrated and innovative array of in vitro readouts and advanced in vivo imaging technolog...the use of a series of advanced and integrated in vitro assays, microscopic readouts, and in vivo imagi... the heart." "We see the integration of in vitro and in vivo readouts becoming increasingly impo...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

...oduct pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs. Safe Harbor Statement This press release conta...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

... are currently using drug combinations against NSCLC and head and neck cancers in two separate U.S. Phase II studies." The investigators examined in vitro combination effects of reovirus alone and in combination with cisplatin, gemcitabine or vinblastine. When reovirus was used alone, it demonstrated sig...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...s the blood-brain barrier has generated much interest in exploring its potential activity in the treatment of patients with advanced brain tumors. In vitro and in vivo data presented at AACR 2009 by investigators from the National Cancer Institute demonstrated that single agent perifosine not only induced...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

...XA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa , including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

...mprove Outcome of Intrauterine Insemination and In vitro Fertilization Procedures LA JOLLA, Calif., Ju... a novel ATP-based drug candidate designed for in vitro (outside of the human body) treatment of sperm in...ction with intrauterine insemination (IUI) and in vitro fertilization (IVF) procedures. ATPotent(TM) is b...

Alfacell Provides Shareholder Update

... to platinum increased tumor growth inhibition from 37% to 73%. These in vitro and in vivo data, which are presently being prepared for publication emp...Another independent study in vivo is underway that may confirm Dr. Pass' in vitro study. After much thought, consideration, and input from highly respe...

HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study

...lution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts. Based on in vitro studies, HP802-247 is expected to release various growth and angiogenic factors into the microenvironment of the wound through administration of thes...

CRi Oosight(TM) Instrument Crucial in IVF Breakthrough Demonstrating a Correlation Between Non-Invasive Egg Metrics and Pregnancy

...ounced today that Oosight(TM), a non-invasive optical imaging system manufactured by CRi and widely used by embryologists as an aid in the field of in vitro fertilization (IVF), has been used in a groundbreaking study that investigated ways to select eggs most likely to produce a pregnancy. Dr. Suha ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

...ies associated with diabetes, kidney disease, cancer chemotherapy and other conditions. In preclinical studies, CXB909 enhanced the action of NGF in vitro , amplifying its activity almost seven-fold. CXB909 was neuroprotective in a variety of cellular assays and in animal models of neuropathies and neur...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

...lid), the only marketed drug in this class. Advantages of torezolid over linezolid include: 4-8 fold greater potency than linezolid in vitro and in vivo In vivo bactericidal activity Activity against all clinically important, gram-positive, drug-resistant strains including t...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

...w for approval by the FDA for the treatment of CAP. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-posit...ve bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide-, and flu...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

...gested that doses as low as 1 mg/kg resulted in circulating levels of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been vaccinated with anthrax vaccine. Anti-toxins such as Valortim(R) are a key element in ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

...oduct pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs. Safe Harbor Statement This press release contains forw...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... mechanism of action, provides beneficial clinical effects in contrast to those achieved with first-generation androgen receptor antagonists." In vitro data recently published in Science provide evidence that MDV3100's novel mechanism of action is unlike that of the leading androgen receptor antagon...

Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients

...iences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosup...

Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy

...iences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosup...

Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes

...mes. When done correctly, PGS can be used to improve the success of in vitro fertilization (IVF) for women of advanced maternal age and recurrent pregna...ch shows that many times IVF fails because a majority of embryos created in vitro are chromosomally abnormal. When done correctly, PGS screens the most impor...

New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns

...deral money. Embryonic stem cells, which have the potential to develop into virtually any cell in the body, are derived from embryos left over from in vitro fertilization (IVF) treatments and would otherwise be destroyed. The Bush approved stem cell lines were derived before the proposed NIH rules an...

Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki

...ections with NXL104 in combination with ceftazidime. The poster provides in vitro data showing that a ceftazidime/NXL104 combination is rapidly bactericidal ...th community acquired pneumonia. The first of the three posters provides in vitro data showing that NXL103 was active against methicillin resistant Staphyloc...

Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests

...hrough laboratories in the U.S. using PCA3 analyte specific reagents (ASR) manufactured by Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both...

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

... cell type found in the tumor vasculature, a key target of anti-PS cancer therapy. The studies also demonstrated the anti-tumor potential of PGN635 in vitro and in a number of animal cancer models. Specifically, in a mouse model of prostate cancer, treatment with a mouse equivalent of PGN635 significantly ...

Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin

...e-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In vitro Diagnostic Medical Devices. For the first time, European clinicians will have access to a rapid test that can simultaneously identify Mycobacterium ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... More About R7128 R7128, a cytidine nucleoside analog inhibitor, is being developed for the treatment of chronic HCV infection. R7128 has shown in vitro activity against all of the most common HCV genotypes. In a 4-week Phase I combination study conducted in 81 treatment-naive pati...

An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients

... 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediated immunity in immunosup...e leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immun...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...he preclinical profile of ANA598 at the EASL Meeting at 4 p.m. CEST (7 a.m. PDT) on Friday, April 24. In an oral presentation, Anadys will present in vitro data showing that combinations of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are...